Business Wire

VIKING-MALT-GROUP

30.8.2021 14:43:06 CEST | Business Wire | Press release

Share
Viking Malt Group: Announcement of New Appointments

Marcin Siemion has decided to leave the Viking Malt Group. He has over many years successfully developed the Viking Malt Polish business and been a key contributor to creating a strong commercial position for Viking Malt Group in the international malting industry. We thank him for his contribution to the company and wish him all the best both privately and professionally. Following this, we would like to announce the following changes in Viking Malt Sales organization:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210830005352/en/

Malin Andersson has been appointed VP Sales in Viking Malt Group

Malin Andersson will be responsible for the sales strategy and the volume customers. She will become a member of the Group Management Team and in her role help Viking Malt in its mission of providing value-adding malted products to our customers for their success. Malin has been with the company since 1997, successfully leading sales, marketing, customer service and logistics in Viking Malt Sweden as well as had the role of a Site Manager and as latest also the role of Managing Director of Viking Malt Sweden. She has in depth knowledge of the company and the industry with a wide international network in malting and brewing industry. She holds an Executive MBA from Copenhagen Business School.

Annika Wilhelmson will lead the Craft and Partner Sales

At the same time, we have the pleasure to announce that Annika Wilhelmson will be responsible for the Craft and Partner Sales and Marketing. She will continue her work in the Group Management Team and cover Innovation, Quality and CSR in the Vice President role. Annika started with Viking Malt Group in 2017 as VP New Business Development. She holds a doctor´s degree in chemical engineering from Helsinki University of Technology and is specialized in malting. Prior to Viking Malt she has worked at VTT in several roles including senior scientist, project manager and Key Account Manager responsible for sales.

Tomasz Malec appointed Viking Malt Poland Managing Director

VP Supply Chain Tomasz Malec will take over the role of the MD of the Viking Malt Polish entity. He continues in his role as the VP Supply Chain and as the member of the Management Team for the Group.

Before Viking Malt Tomasz Malec worked for Carlsberg for almost twenty years, latest as the VP Production for Carlsberg Poland. Prior to Carlsberg he has worked for Elkometech, Danfoss and Computerland SA as well as Huta Auluminimum Konin SA in different roles. Tomasz holds a degree in engineering from Łódź Technical University, Poland.

“I am delighted to offer these important roles to three of our key leaders. I feel confident that we will continue to serve our customers around the world with high quality malt - and secure that the company with over 130 years of history will stay strong for many years to come“, says CEO Kasper Madsen.

Viking Malt Group has production in 5 countries: Finland, Sweden, Denmark and Lithuania as well as two plants in Poland. The production capacity is 600 000 t/a and the turnover of the group is appr. 250 million euros and the company employ appr. 260 employees. Viking Malt is the largest malting company in Scandinavia, 5th largest in Europe and 9th in the world. It is the leading company in specialty malts in the global market. Viking Malt Group is owned by Polttimo (62,5 %) and Svenska Lantmännen (37,5 %).

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release

The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u

Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release

Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye